A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
News|Articles|September 25, 2026
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
Author(s)Anita Nelson, MD
Fact checked by: Joshua Fitch, Senior Editor
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Advertisement
Advertisement
In January 2026,
Related to this article
Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
Advertisement
Advertisement